Madrigal Pharmaceuticals, Inc. - Common Stock (NQ:MDGL)

486.88 -5.95 (-1.21%)

Streaming Delayed Price Updated: 10:49 AM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Madrigal Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Where Will Madrigal Pharmaceuticals Be in 3 Years? ↗

June 15, 2024

The coast is clear for it to grow, for now.

Via The Motley Fool

Madrigal Pharmaceuticals Stock Earns RS Rating Upgrade ↗

June 12, 2024

On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.

Via Investor's Business Daily

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 11, 2024

Via Benzinga

Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗

June 10, 2024

Success isn't guaranteed, but both companies could become big winners.

Via The Motley Fool

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗

June 05, 2024

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....

Via Benzinga

Is Madrigal Pharmaceuticals Stock a Buy? ↗

May 21, 2024

It's not the most prominent biotech, but it has an important claim to fame.

Via The Motley Fool

2 Under-the-Radar Growth Stocks to Consider ↗

April 10, 2024

Don't ignore these innovative companies.

Via The Motley Fool

1 No-Brainer Growth Stock to Buy Now ↗

April 03, 2024

This liver-disease specialist might be significantly undervalued.

Via The Motley Fool

Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH ↗

June 05, 2024

Researchers published results Wednesday showing Lilly's weight-loss drug could work in a liver disease.

Via Investor's Business Daily

DouYu International Posts Q1 Results, Joins Annexon, Dollar Tree And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

June 05, 2024

Via Benzinga

Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug ↗

June 04, 2024

Viking Therapeutics stock falls despite seemingly positive test results for a drug that treats a serious liver disease.

Via Investor's Business Daily

The Week Ahead: What's Next ↗

June 02, 2024

The core part of our portfolio is up 24% this year ... and we're about to add another stock. Plus, a riddle.

Via Talk Markets

MDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024 ↗

May 07, 2024

MDGL stock results show that Madrigal Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Here's 1 Huge New Reason to Buy Madrigal Pharmaceuticals Stock ↗

March 26, 2024

This biotech just got clearance to dive into a deep ocean of a market.

Via The Motley Fool

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 07, 2024

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

May 03, 2024

Via Benzinga

6 Stocks Positioned to Soar as Investors Focus on MASH

April 22, 2024

Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of...

Via TheNewswire.com

7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024 ↗

April 15, 2024

Analyst-backed stocks have a high correlation with future stock price growth. Here are seven stocks with a high number of recent upgrades.

Via InvestorPlace

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics ↗

April 05, 2024

These businesses should see good times ahead.

Via The Motley Fool

The 3 Best Biotech Stocks to Buy in April 2024 ↗

April 01, 2024

Biotech is one of the hottest sectors on the market, creating big opportunities for some of the best biotech stocks to buy in April.

Via InvestorPlace

2 Top Biotech Buyout Candidates ↗

March 31, 2024

Investors who are adventurous, have a high-risk tolerance, and are home run hitters may opt for biotech stocks. Investors in this group may want to hone in on stocks that have the potential to be...

Via Talk Markets

Better Buy: Viking Therapeutics vs. Madrigal Pharmaceuticals ↗

March 29, 2024

Both stocks are pretty risky, but one of them more so than the other.

Via The Motley Fool

Is This Healthcare Stock a Screaming Buy After Scoring a Huge Drug Approval? ↗

March 29, 2024

Could it be just a matter of time before Madrigal Pharmaceuticals stock takes off?

Via The Motley Fool

7 Stocks That Will Drive the Weight Loss Drugs Market

March 28, 2024

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Via MarketBeat

This Under-the-Radar Stock Just Hit a Major Milestone: Time to Buy? ↗

March 22, 2024

The mid-cap biotech has succeeded where many others failed.

Via The Motley Fool

Is Madrigal Pharmaceuticals Stock a Better Buy Than Eli Lilly and Novo Nordisk After Its Huge FDA Win? ↗

March 19, 2024

Madrigal has one key advantage over its two huge potential future rivals.

Via The Motley Fool

7 Biotech Stocks Ready to Ride the Sector’s Resurgence ↗

March 18, 2024

With investors seeking new opportunities with certain segments appearing stretched, biotech stocks offer a viable canvas.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Hits 80-Plus Relative Strength Rating Benchmark ↗

March 18, 2024

On Monday, Madrigal Pharmaceuticals stock hit a key technical milestone, seeing its Relative Strength Rating jump to 83 from 69 a day ago.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

March 18, 2024

Via Benzinga

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗

March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.